57 results about "Pancreatic Endocrine Secretion" patented technology

The invention relates to the discovery of a selective cell surface marker that permits the selection of a unique subset of pancreatic stems cells having a high propensity to differentiate into insulin producing cells or into insulin producing cell aggregates.

The invention provides pluripotent cells modified to overexpress Pdx1 and Ngn3. Pluripotent cells include embryonic stem cells and induced pluripotent stem cells. Methods of producing pancreatic endocrine progenitor cells from ES cells or from iPS cells by forced expression of Pdx1 and Ngn3 are provided. Pancreatic endocrine progenitor cells are useful for drug discovery and cell replacement therapy.

The invention relates to the discovery that the proliferation and survival of pancreatic progenitor cells can be enhanced by contacting the cells with, (1) a caspase inhibitor sufficient to reduce apoptosis in the pancreatic endocrine cells; and, (2) a growth factor in an amount sufficient to increase the level of activated Akt in the pancreatic endocrine cells.

The present invention provides novel methods and compositions for the diagnosis, prognosis and treatment of pancreatic cancer. The invention also provides methods of identifying anti-pancreatic cancer agent.

The invention relates to the discovery of a selective cell surface marker that permits the selection of a unique subset of pancreatic stem cells having a high propensity to differentiate into insulin-producing cells or into insulin-producing cell aggregates.

The invention provides for methods of differentiating pancreatic endocrine cells into pancreatic beta cells expressing PDX1, NKX6.1, MAFA, UCN3 and SLC2A. These pancreatic beta cells may be obtained by step-wise differentiation of pluripotent stem cells. The pancreatic beta cells exhibit glucose-dependent mitochondrial respiration and glucose-stimulated insulin secretion similar to islet cells.

Disclosed are new methods for pancreatic β-cell regeneration and the methods for identifying adult pancreatic endocrine stem cells and the methods for identifying the existence of differentiation processes from adult pancreatic endocrine stem cells toward pancreatic β-cell fate and a new animal model for pancreatic β-cell regeneration. The present invention can be utilized in screening and development of new medicines and therapy protocols for diabetes.

The invention discloses an application of SUSD2 protein as a marker and particularly provides an application of the SUSD2 protein as the marker in identification, selection or separation of pancreas internal secretion precursor cells and / or newborn pancreas internal secretion cells, and an application of an mRNA, for encoding the SUSD2 protein, of a precursor protein as the marker in identification of the pancreas internal secretion precursor cells and / or the newborn pancreas internal secretion cells. In the invention, through analysis of gene expression of pancreas entoderm cells sourced by induced directional differentiation of human pluripotent stem cells, enrichment expression of a SUSD2 gene in the ancreas internal secretion precursor cells and the newborn pancreas internal secretion cells is found. In addition, a protein encoded by the SUSD2 gene is a receptor protein on cell membranes. With the protein as the marker, the identification, the selection or the separation of the pancreas internal secretion precursor cells and the newborn pancreas internal secretion cells can be carried out, which has an important significance on research of pancreas relative cells in various growing periods.

This invention relates to the in vitro differentiation of pluripotent cells into pancreatic progenitors by i) culturing pluripotent cells in a definitive endoderm (DE) medium comprising a TGFp ligand, fibroblast growth factor ( FGF), bone morphogenetic protein (BMP), a PI3K inhibitor and optionally a GSK3 β inhibitor to produce a population of definitive endoderm cells, ii) culturing the definitive endoderm cells in a first pancreatic medium comprising an activin antagonist; FGF; retinoic acid; and a BMP inhibitor to produce a population of dorsal foregut cells; iii) culturing the dorsal foregut cells in a second pancreatic medium comprising FGF, retinoic acid, a BMP inhibitor, and a hedgehog signalling inhibitor, and; iv) culturing the endoderm cells in a third pancreatic medium comprising FGF. The progenitor cells thus produced may be further differentiated into pancreatic endocrine cells. These methods may be useful, for example, in producing pancreatic cells for therapy or disease modelling.

The present invention provides methods to promote the differentiation of pluripotent stem cells into insulin producing cells. In particular, the present invention provides a method utilizing an agent that degrades retinoic acid to produce a population of pancreatic endocrine precursor cells.

A method for separating and culturing insulin dry cell from pancreatic tissue and inducing into pancreatic cell is carried out by separating pancreatic cell aggregate, adding it into culture dish with culture medium A for 2-5days, inoculating suspended pancreatic cell aggregate into culture dish with culture medium B, culturing for 6-20days to grow asteriform pancreatic dry cell, sub-culturing to obtain pancreatic dry cell, inoculating it culture dish with culture medium C, culturing for 2-5days, replacing culture medium C with culture medium D, and culturing for 4-15days to obtain the final product.

A method for preparing a preparation of mammalian pancreatic endocrine cells comprising the steps: dissociating intact pancreatic tissue into a cell suspension comprising single cells and cell aggregates; enriching said cell suspension with regard to the content in endocrine cells by separating single cells and cellular aggregates with size <100 mum; and removing contaminating non-endocrine cells by density centrifugation.

The invention discloses a culture method for preparing pancreatic beta cells by inducing directional differentiation of pluripotent stem cells. The culture method comprises the following specific steps: S100, preparing induced multifunctional cell spheres; S200, performing primary differentiation, namely performing directional differentiation culture on the induced multifunctional cell spheres by using a culture solution A to obtain fixed endoderm cells; S300, performing secondary differentiation, namely performing induced differentiation on the fixed endoderm cells by using a culture solution B to obtain pancreatic precursor cells; S400, performing third differentiation, namely performing induced differentiation on the pancreatic precursor cells by using a culture solution C to obtain pancreatic endocrine progenitor cells; and S500, performing fourth differentiation, namely performing induced differentiation on the pancreatic endocrine progenitor cells by using a culture solution D to obtain the required pancreatic beta cells. The culture solutions have different proportions in different stages of cell culture, each component directionally plays a role in stages, and the induced multifunctional stem cells can be directionally differentiated and cultured in a short time by the method to obtain the pancreatic beta cells.

The invention relates to a method of identifying and obtaining a culture cells comprising cells selected from the group consisting of endocrine pre-progenitor cells, endocrine progenitor cells, early endocrine cells, and / or fully differentiated endocrine cells. Also contemplated is a method of expanding the number of such cells as well as sorting such cells. In some aspects the invention further relates to a selective cell surface marker, DNER, that permits the selection of a unique subset of cells with endocrine pre-progenitor, endocrine progenitor, early endocrine, and / or fully differentiated endocrine phenotype. In some aspects the selective cell surface marker is selected from the group consisting of DNER, DISP2, SEZ6L2, LRP1 1 and SLC30A8. Furthermore, the invention relates to isolated cells selected from such cells and compositions thereof.

The current invention provides for methods and systems of inducing cell cycle exit and terminal differentiation in stem cells undergoing differentiation into various mature cell types in particular pancreatic endocrine cells. The current invention also provides for methods and systems of inducing differentiation of pancreatic endocrine cells from stem cells. The invention also provides for the cells produced by the methods that are suitable for transplantation or grafting into a subject for the prevention and / or treatment of disease, and useful for basic research and drug testing.

The present invention is directed to methods to treat pluripotent cells, whereby the pluripotent cells can be efficiently expanded in culture and differentiated by treating the pluripotent cells with an inhibitor of GSK-3B enzyme activity.

The present invention relates to methods of selecting pancreatic endocrine cells from total pancreatic cells by incubation with protein synthesis inhibitors.

The present invention provides methods of identifying endocrine stem and progenitor cells.

The invention relates to a method of identifying, obtaining and / or quantifying a culture of pancreatic cells selected from the group consisting of ductal / endocrine progenitor cells, endocrine progenitor cells, early endocrine cells, and fully differentiated endocrine cells. Also contemplated is a method of expanding the numbers of such cells as well as sorting such cells. The invention further relates to a selective cell surface marker, DDR1, that permits the selection of a unique subset of cells with pancreatic endocrine progenitor phenotype. Furthermore, the invention relates to isolated cells selected from such cells and compositions thereof.

The present invention relates to methods of producing pancreatic endocrine cells and uses of the cells obtained using the methods. The method utilises inhibitors or combinations of factors to provide increased quantities of endocrine material, for example for transplantation purposes.

Provided herein are therapies, and methods using that therapy, in the treatment of one or more of Type 2 diabetes (T2D), obesity, glucose intolerance and insulin resistance or to control weight gain in subjects. In particular, the subject may be candidates for treatment with one or more small molecule anti-diabetic drugs and the therapy may include implanting a population of pancreatic endocrine progenitor cells into the subject, where the cells are allowed to mature in vivo to produce a population.

The invention relates to a pancreatic stem cell preparation method and a special culture medium composition therefor, and concretely discloses a method for obtaining pancreatic stem cells by inducing human mesenchymal stem cells, and a matched culture medium composition thereof. The method is characterized in that a two-step induction process is used to obtain definitive endoderm cells and pancreatic stem cells in vitro once, cells in all stages can express corresponding specific genes, and the obtained pancreatic stem cells differentiate to become functional pancreatic endocrine cells and pancreatic exocrine cells. The obtained pancreatic stem cells can be used for treating the pancreatic injury caused by diabetes and the like, provides experiment bases and clinic research evidences for the cell treatment of the pancreatic injury diseases, and provides a new way for the cell transplant treatment.

The present invention provides a method for lowering blood glucose levels in an animal by transplanting a population of pancreatic endocrine precursor cells into an animal.